Pioglitazone inhibits high glucose‑induced synthesis of extracellular matrix by NF‑κB and AP‑1 pathways in rat peritoneal mesothelial cells

Zhou,Guangyu; Su,Xuesong; Ma,Jianfei; Wang,Lining; Li,Detian

doi:10.3892/mmr.2013.1309

Pioglitazone inhibits high glucose‑induced synthesis of extracellular matrix by NF‑κB and AP‑1 pathways in rat peritoneal mesothelial cells

Authors:
- Guangyu Zhou
- Xuesong Su
- Jianfei Ma
- Lining Wang
- Detian Li
View Affiliations

Affiliations: Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: February 6, 2013 https://doi.org/10.3892/mmr.2013.1309
Pages: 1336-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High glucose (HG) in peritoneal dialysates has been demonstrated to induce extracellular matrix (ECM) synthesis by peritoneal mesothelial cells (PMCs) and to contribute to peritoneal fibrosis during continuous ambulatory peritoneal dialysis (CAPD). In the present study, we investigated the effects of pioglitazone, a peroxisome proliferator‑activated receptor γ (PPARγ) agonist, on HG‑induced ECM accumulation and the underlying mechanism in rat PMCs (RPMCs). In cultured RPMCs, HG treatment increased the expression of fibronectin (FN), collagen I and plasminogen activation inhibitor‑1 (PAI‑1) at the mRNA and protein levels, while it downregulated the expression of PPARγ in a time‑ and concentration‑dependent manner. Pretreatment with pioglitazone not only decreased the expression of PAI‑1 and matrix proteins (FN and collagen I), but prevented the downregulation of PPARγ in RPMCs under HG conditions. HG treatment activated the nuclear factor‑κB (NF‑κB) and activator protein‑1 (AP‑1) pathways. In addition, the NF‑κB inhibitor, pyrrolidine dithiocarbamate (PDTC), and the AP‑1 inhibitor, SP600125, decreased the protein levels of FN, collagen I and PAI‑1, suggesting a role for the NF‑κB and AP‑1 pathways in the regulation of ECM accumulation induced by HG in RPMCs. Notably, we demonstrated that pretreatment with pioglitazone significantly inhibited HG‑induced NF‑κB and AP‑1 activation. Collectively, these results suggest that pioglitazone inhibits HG‑induced ECM accumulation in RPMCs by increasing PPARγ expression, and by inhibiting the NF‑κB and AP‑1 pathways.

View Figures

View References

1	Dobbie JW: Ultrastructure and pathology of the peritoneal dialysis. The Textbook of Peritoneal Dialysis. Gokal R and Nolph KD: 3rd edition. Kluwer Academic Publishers; New York, NY: pp. 17–44. 1994, View Article : Google Scholar
2	Dobbie JW: Peritoneal ultrastructure and changes with continuous ambulatory peritoneal dialysis. Perit Dial Int. 13(Suppl 2): S585–S587. 1993.PubMed/NCBI
3	Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS and Yung S: Emodin ameliorates glucose- induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int. 64:519–533. 2003. View Article : Google Scholar : PubMed/NCBI
4	Katsutani M, Ito T, Masaki T, Kohno N and Yorioka N: Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK1/2. Ther Apher Dial. 11:94–100. 2007. View Article : Google Scholar
5	Brown JD and Plutzky J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 115:518–533. 2007. View Article : Google Scholar : PubMed/NCBI
6	Zafiriou S, Stanners SR, Polhill TS, Poronnik P and Pollock CA: Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int. 65:1647–1653. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK, Han JY and Cha DR: Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 23:2750–2760. 2008. View Article : Google Scholar : PubMed/NCBI
8	Panchapakesan U, Sumual S, Pollock CA and Chen X: PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol. 289:F1153–F1158. 2005. View Article : Google Scholar : PubMed/NCBI
9	Ma LJ, Marcantoni C, Linton MF, Fazio S and Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 59:1899–1910. 2001. View Article : Google Scholar
10	Peng Y, Liu H, Liu F, Liu Y, Li J and Chen X: Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton). 11:516–523. 2006. View Article : Google Scholar : PubMed/NCBI
11	Zhang YF, Yang X, Zhang YJ, Sun YL, Zou XL, Kong QY, Dong XQ, Ye XQ and Yu XQ: Peroxisome proliferator-activated receptor-gamma is expressed by rat peritoneal mesothelial cells: its potential role in peritoneal cavity local defense. Am J Nephrol. 26:602–611. 2006. View Article : Google Scholar
12	Bozkurt D, Taskin H, Sezak M, Biçak S, Sen S, Ok E and Duman S: Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model. Adv Perit Dial. 24:32–38. 2008.
13	Yao Q, Pawlaczyk K, Ayala ER, Kuzlan M, Styszynski A, Breborowicz A, Heimburger O, Qian J, Stenvinkel P, Axelsson J and Lindholm B: Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. Blood Purif. 24:575–582. 2006. View Article : Google Scholar
14	Hjelle JT, Golinska BT, Waters DC, Steidley KR, McCarroll DR and Dobbie JW: Isolation and propagation in vitro of peritoneal mesothelial cells. Perit Dial Int. 9:341–347. 1989.PubMed/NCBI
15	Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF and Russell GI: What really happens to people on long-term peritoneal dialysis? Kidney Int. 54:2207–2217. 1998. View Article : Google Scholar : PubMed/NCBI
16	Ha H and Lee HB: Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int. 20(Suppl 2): S15–S18. 2000.PubMed/NCBI
17	Devuyst O, Topley N and Williams JD: Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant. 17(Suppl 3): 12–15. 2002. View Article : Google Scholar : PubMed/NCBI
18	Jorres A, Williams JD and Topley N: Peritoneal dialysis solution biocompatibility: inhibitory mechanisms and recent studies with bicarbonate-buffered solutions. Periton Dial Int. 17:S42–S46. 1997.
19	Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L and Noble NA: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 112:379–388. 2003. View Article : Google Scholar
20	Higuchi C, Tanihata Y, Nishimura H, Naito T and Sanaka T: Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher Dial. 9:173–181. 2005. View Article : Google Scholar : PubMed/NCBI
21	Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T and Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 49:1022–1032. 2000. View Article : Google Scholar
22	Pelzer T, Jazbutyte V, Arias-Loza PA, Segerer S, Lichtenwald M, Law MP, Schäfers M, Ertl G and Neyses L: Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats. Biochem Biophys Res Commun. 329:726–732. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yuan X, Zhang Z, Gong K, Zhao P, Qin J and Liu N: Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Biol Pharm Bull. 34:618–623. 2011. View Article : Google Scholar
24	Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM and Halperin JA: Anticancer effect of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 61:6213–6218. 2001.PubMed/NCBI
25	Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C and Casini A: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 122:1924–1940. 2002. View Article : Google Scholar : PubMed/NCBI
26	Bowie A and O’Neill LA: Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol. 59:13–23. 2000. View Article : Google Scholar : PubMed/NCBI
27	Chen F, Castranova V and Shi X: New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 159:387–397. 2001. View Article : Google Scholar : PubMed/NCBI
28	Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Neriah Y and Baeuerle PA: Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature. 365:182–185. 1993. View Article : Google Scholar : PubMed/NCBI
29	Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R and Nawroth PP: The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors. 10:157–167. 1999. View Article : Google Scholar : PubMed/NCBI
30	Nishio Y, Kashiwagi A, Taki H, Shinozaki K, Maeno Y, Kojima H, Maegawa H, Haneda M, Hidaka H, Yasuda H, et al: Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes. 47:1318–1325. 1998. View Article : Google Scholar : PubMed/NCBI
31	Chinenov Y and Kerppola TK: Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene. 20:2438–2452. 2001. View Article : Google Scholar : PubMed/NCBI
32	Shaulian E and Karin M: AP-1 in cell proliferation and survival. Oncogene. 20:2390–2400. 2001. View Article : Google Scholar : PubMed/NCBI
33	Ahn JD, Morishita R, Kaneda Y, Lee KU, Park JY, Jeon YJ, Song HS and Lee IK: Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose-and angiotensin II-induced type 1 plasminogen activator inhibitor (PAI-1) gene expression in cultured human vascular smooth muscle cells. Diabetologia. 44:713–720. 2001. View Article : Google Scholar
34	Jeong IK, Oh da H, Park SJ, Kang JH, Kim S, Lee MS, Kim MJ, Hwang YC, Ahn KJ, Chung HY, et al: Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Exp Mol Med. 43:684–692. 2011.
35	Chen S, Khan ZA, Cukiernik M and Chakrabarti S: Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab. 284:E1089–E1097. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chen J and Mehta JL: Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol. 291:H1738–H1745. 2006. View Article : Google Scholar : PubMed/NCBI
37	Chen S, Mukherjee S, Chakraborty C and Chakrabarti S: High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol. 284:C263–C272. 2003. View Article : Google Scholar : PubMed/NCBI
38	Arnold R and König W: Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology. 346:427–439. 2006. View Article : Google Scholar
39	Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM and Stemerman MB: Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 277:34176–34181. 2002. View Article : Google Scholar